From mechanism to resistance – changes in the use of dexamethasone in the treatment of multiple myeloma

References

• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(8):995.
   PubMed Web of Science ®Google Scholar
• Sudalagunta P, Silva MC, Canevarolo RR, et al. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine. 2020;54:102716.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015;33(7):732–739.
   PubMed Web of Science ®Google Scholar
• Hassan Zafar M, Khan A, Aggarwal S, et al. Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma. South Asian J Cancer. 2018;7(1):58–60.
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–2400.
   PubMed Web of Science ®Google Scholar
• Burki TK. Selinexor and dexamethasone in multiple myeloma. Lancet Oncol. 2018;19(3):e146.
   PubMed Web of Science ®Google Scholar
• Arth GE, Fried J, Johnston DBR, et al. 16-Methylated steroids. II. 16α-methyl analogs of cortisone, a new group of anti-inflammatory steroids. 9α-halo derivatives. J Am Chem Soc. 1958;80(12):3161–3163.
   Web of Science ®Google Scholar
• Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14(18):2314–2329.
   PubMed Web of Science ®Google Scholar
• Rowland TL, McHugh SM, Deighton J, et al. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone. Immunol Lett. 1999;68(2–3):325–332.
   PubMed Web of Science ®Google Scholar
• Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 1995;15(2):943–953.
   PubMed Web of Science ®Google Scholar
• Tao Y, Williams-Skipp C, Scheinman RI. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NFkappa B and induction of apoptosis. J Biol Chem. 2001;276(4):2329–2332.
   PubMed Web of Science ®Google Scholar
• Helmberg A, Auphan N, Caelles C, et al. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. Embo J. 1995;14(3):452–460.
   PubMed Web of Science ®Google Scholar
• Bladh LG, Liden J, Dahlman-Wright K, et al. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol Pharmacol. 2005;67(3):815–826.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135–142.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011;29(32):4243–4249.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Barlogie B, SUMMIT/CREST Investigators, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929–934.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–5321.
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez AD, Quwaider M, Canavese EM, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res. 2014;20(6):1542–1554.
   PubMed Web of Science ®Google Scholar
• Xu J, Pfarr N, Endris V, et al. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis. 2017;6(5):e337.
   PubMedGoogle Scholar
• Dehghanifard A, Kaviani S, Abroun S, et al. Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin Lymphoma Myeloma Leuk. 2018;18(5):311–320.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999;18(48):6733–6740.
   PubMed Web of Science ®Google Scholar
• Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol. 2019;98(1):19–28.
   PubMed Web of Science ®Google Scholar
• Bao L, Ruan GR, Lu XJ, et al. Abnormal expression of programmed cell death 5 gene in multiple myeloma patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18(3):634–637.
   PubMedGoogle Scholar
• Liu J, Li X, Gui R, et al. Effect of human recombinant PDCD5 protein on cell apoptosis of multiple myeloma KM3 cells induced by dexamethasone and its mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35(7):725–731.
   PubMedGoogle Scholar
• Cheng Q, Liu L, Fu Y, et al. RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the WNT signalling pathway. Clin Exp Pharmacol Physiol. 2018;45(2):140–145.
   PubMed Web of Science ®Google Scholar
• Faiman B, Bilotti E, Mangan PA, IMF Nurse Leadership Board, et al. Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF nurse leadership board. Clin J Oncol Nurs. 2008;12(3 Suppl):53–63.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. NIH publication 09-7473. Published May 29, 2009; Revised June 14, 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed 09 September 2022
   Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, Eastern Cooperative Oncology Group, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113.
   PubMed Web of Science ®Google Scholar
• Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol. 2007;136(2):203–211.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–6249s.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, International Myeloma Working Group, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3(1):17–21.
   PubMedGoogle Scholar
• Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359–2367.
   PubMed Web of Science ®Google Scholar
• Bertolotti P, Bilotti E, Colson K, et al. Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the international myeloma foundation’s nurse leadership board. Clin J Oncol Nurs. 2008;12(3 Suppl):9–12.
   PubMed Web of Science ®Google Scholar
• King T, Faiman B. Steroid-Associated side effects: a symptom management update on multiple myeloma treatment. Clin J Oncol Nurs. 2017;21(2):240–249.
   PubMed Web of Science ®Google Scholar
• Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027–3036.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA, Delasalle K, et al. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80(4):887–890.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, POLLUX Investigators, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Wandler AM, Huang BJ, Craig JW, et al. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020;34(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li F, Saha MN, et al. miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 2015;21(10):2399–2411.
   PubMed Web of Science ®Google Scholar
• Wang X, Li C, Ju S, et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma. 2011;52(10):1991–1998.
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Fey V, Thomas C, et al. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol. 1998;13(2):397–405.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li R, Zhu Y, et al. Dihydroartemisinin induces growth arrest and overcomes dexamethasone resistance in multiple myeloma. Front Oncol. 2020;10(767), https://doi.org/10.3389/fonc.2020.00767
   Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630–4634.
   PubMed Web of Science ®Google Scholar
• Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27(2):464–472.
   PubMed Web of Science ®Google Scholar
• Nojima M, Maruyama R, Yasui H, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res. 2009;15(13):4356–4364.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131–144.
   PubMed Web of Science ®Google Scholar
• Bassan F, Peter F, Houbre B, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care. 2014;23(1):22–35.
   PubMed Web of Science ®Google Scholar
• Sweiss K, Wirth SM, Sharp L, et al. Collaborative Physician-Pharmacist-Managed multiple myeloma clinic improves guideline adherence and prevents treatment delays. J Oncol Pract. 2018;14(11):e674–e682.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Acosta M. Comparative safety, bioavailability, and pharmacokinetics of oral dexamethasone, 4-mg and 20-mg tablets, in healthy volunteers under fasting and fed conditions: a randomized open-label, 3-way crossover study. Clin Lymphoma Myeloma Leuk. 2020;20(11):768–773.
   PubMed Web of Science ®Google Scholar